Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMontreal Heart Institute
About this trial
The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.
Eligibility criteria
Qualifiers
18 years of age or older, capable to provide informed consent;
Referred for a FDG-PET/CT study
Classified as having Possible IE prior to FDG-PET/CT imaging;
Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.
Disqualifiers
Subjects with prosthetic cardiac valve and/or CIED;
Pregnant or breastfeeding female;
Body mass index > 45 kg/m2.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
97 Participants
are grouped into 1 trial groupLocations
6Centre Hospitalier de l'Universite de MontrealH2X 3E4, MontrealQuebec, Canada
Jewish General HospitalH3T 1E2, MontrealQuebec, Canada
McGill University Health CenterH4A 3J1, MontrealQuebec, Canada
Montreal Heart InstituteH3l 3c1, MontrealQuebec, Canada
Sponsors and collaborators
Montreal Heart Institute
Lead sponsor
Source ClinicalTrials.gov